尤瑞克林联合替罗非班治疗超溶栓 时间窗急性脑梗死的临床研究
作者:
作者单位:

作者简介:

张奎,男,主治医师,主要研究方向是脑血管病的治疗。

通讯作者:

中图分类号:

R 743.33

基金项目:


Clinical Study of Urinary Kallikrein Combined with Tirofiban in the Treatment of Acute Cerebral Infarction with Super Thrombolytic Time Window
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    摘 要目的:分析超溶栓时间窗急性脑梗死应用尤瑞克林联合替罗非班的临床效果,并观察血清中的炎症因子 指标白细胞介素(IL)–6 和肿瘤坏死因子 α(TNF–α)水平的变化。 方法:选取 2021 年 5 月至 2022 年 5 月濮阳油田 总医院脑血管病病区收治的超溶栓时间窗的急性脑梗死患者 86 例,随机分为观察组和对照组,各 43 例。对照组给予 尤瑞克林治疗,观察组给予尤瑞克林联合替罗非班治疗。比较两组患者神经功能缺损情况、日常生活活动能力、炎症 因子水平、不良反应发生情况。 结果:治疗后 14 d、30 d,观察组患者美国国立卫生研究院脑卒中量表(NIHSS)评 分低于对照组,Barthel 指数评分高于对照组,差异具有统计学意义(P < 0.05)。治疗后 14 d,观察组患者 IL–6、 TNF–α 水平低于对照组,差异具有统计学意义(P < 0.05)。两组患者不良反应发生率比较,差异无统计学意义 (P > 0.05)。 结论:对已超过溶栓时间窗的急性脑梗死患者给予尤瑞克林、替罗非班治疗,可提高临床疗效,减轻 炎症反应,同时不会增加不良反应。

    Abstract:

    AbstractObjective To analyze the clinical effect of urinary kallikrein combined with tirofiban in acute cerebral infarction with super thrombolytic time window, and observe the changes of serum inflammatory factor index interleukin (IL) -6 and tumor necrosis factor α (TNF-α) levels. Methods A total of 86 patients with acute cerebral infarction with super thrombolytic time window admitted to cerebrovascular disease ward of Puyang Oilfield General Hospital from May 2021 to May 2022 were randomly divided into an observation group and a control group, with 43 cases in each group. The control group was treated with urinary kallikrein, and the observation group was treated with urinary kallikrein combined with tirofiban. The neurological deficits, daily living activities and the levels of inflammatory factors and the occurrence of adverse reactions were compared between the two groups. Results At 14 and 30 days after treatment, the National Institutes of Health stroke scale (NIHSS) score of the observation group was lower than that of the control group, and the Barthel index score was higher than that of the control group, with statistical significance (P < 0.05). 14 days after treatment, the levels of IL-6 and TNF-α in the observation group were lower than those in the control group, and the differences were statistically significant (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion For patients with acute cerebral infarction whose super thrombolytic time window has been exceeded, the treatment of urinary kallikrein and tirofiban can improve the clinical efficacy, reduce the inflammatory response, and do not increase the adverse reactions.

    参考文献
    相似文献
    引证文献
引用本文
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2023-12-22
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2024-06-28
  • 出版日期:
重要通知

近期有不法分子冒充我刊名义给作者打电话或发邮件,编造各种理由要求添加微信或QQ、伪造复制我刊编辑部公章发放假冒录用通知书等等各种方式试图骗取作者钱财。我刊在此郑重声明:(1)杂志社与作者沟通方式为电话和邮件,在杂志社官方网站(http://www.szzxyjh.com)“联系我们”下拉菜单,或者网站最下端信息栏可以查询),绝对不会要求作者添加微信或QQ。此网站为我刊唯一官方网站,其他均为假冒网站。(2)我刊录用稿件仅收取合理版面制作费和审稿费,收款单位为“深圳市第二人民医院”对公账户,其他涉及私人账户者均为假冒。望广大作者提高警惕,谨防上当。谢谢配合!
《深圳中西医结合杂志》编辑部

关闭